Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 5/20 | 0.41 |
| ▸ | MERTK | Q12866 | 5/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21593220 | 0.84 | NR1H2 (0.43) | NR1H2BRAFESR2 | |
| SCHEMBL21593123 | 0.84 | NR1H2 (0.48) | ROCK2NR1H2ACACBESR2AXL | |
| SCHEMBL21593214 | 0.83 | TBK1 (0.40) | ROCK2ROCK1CDC42BPBNR1H2ACACB | |
| SCHEMBL21593079 | 0.83 | RAF1 (0.40) | NR1H2BRAFESR2LRRK2 | |
| SCHEMBL21593081 | 0.83 | NR1H2 (0.40) | ROCK2ROCK1CDC42BPBNR1H2ACACB | |
| SCHEMBL21593101 | 0.83 | NR1H2 (0.40) | ROCK2ROCK1CDC42BPBNR1H2ACACB | |
| SCHEMBL21593226 | 0.83 | BUB1 (0.40) | ROCK2ROCK1CDC42BPBNR1H2ACACB | |
| SCHEMBL21593228 | 0.82 | PORCN (0.41) | ROCK2ROCK1CDC42BPBNR1H2ACACB | |
| SCHEMBL21593077 | 0.82 | HCRTR2 (0.41) | ROCK2ROCK1CDC42BPBNR1H2ACACB | |
| SCHEMBL21593216 | 0.82 | NR1H2 (0.38) | ROCK2ROCK1CDC42BPBNR1H2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885CDC42BPB 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.